Pharma-Bio Serv Reports Q1 2025 Growth with Increased Revenues and Improved Profit Margins

Pharma-Bio Serv, Inc. (OTCMKTS: PBSV) has reported its quarterly financial results for the period ending January 31, 2025. The company provides consulting services to the pharmaceutical, biotechnology, and medical device industries across several regions, including Puerto Rico, the United States, and Europe.

Key Financial Highlights:

• Total Revenues: $2,471,333 in Q1 2025, an increase from $2,380,187 in Q1 2024.
• Gross Profit: Rose to $768,109, up from $535,609 the previous year, indicating improved efficiency.
• Net Income: Minimal profit of $8,536 compared to a loss of $(270,719) in the same quarter last year.
• Basic and Diluted Earnings per Share: $0.000, a substantial recovery from $(0.012) in Q1 2024.
• Cash and Cash Equivalents: Increased to $7,307,123, compared to $6,767,356 from the previous quarter.
• Total Assets: $16,077,494 as of January 31, 2025, a slight decrease from $16,292,230 in October 2024.

Positive Aspects:

• Significant gross profit margin improvement from 22.5% in Q1 2024 to 31.1% in Q1 2025, driven by high-margin projects in the European market.
• Reduction in Selling, General and Administrative Expenses (SG&A) by about $113,609 to $860,300, contributing to the improved loss scenario.
• Increased revenue from consulting services in Europe, climbing from $64,805 in Q1 2024 to $721,258 in Q1 2025.

Negative Aspects:

• Despite the improvement in revenues and gross profits, the company still reported a loss from operations of $(92,191).
• The Puerto Rico consulting segment saw revenue decline to $1,103,269 from $1,390,609, indicating challenges in maintaining client engagements.
• Net comprehensive loss due to fluctuations from foreign currency translations, which saw a loss of $(18,497).

Outlook:

Pharma-Bio Serv, Inc. anticipates continued challenges in capturing revenue within competitive local and global markets. However, management is optimistic about strategic realignments and future opportunities in high-margin projects, particularly in Europe. The company holds a tax exemption grant with PRIDCO that is crucial for maintaining its competitive edge.

Investors should keep an eye on further developments, especially regarding the pending extension of the tax grant that expires in October 2024 and any recovery actions related to outstanding receivables.